Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Copaxone interferes with the PrP Sc-GAG interaction.

R Engelstein1, H Ovadia, R Gabizon

  • 1Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, Jerusalem, Israel.

European Journal of Neurology
|July 31, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a topical bacteriophage gel targeting <i>Cutibacterium acnes</i> for acne prone skin and results of a phase 1 cosmetic randomized clinical trial.

Skin health and disease·2022
Same author

Prestin autoantibodies screening in idiopathic sudden sensorineural hearing loss.

European annals of otorhinolaryngology, head and neck diseases·2019
Same author

Multiple pathways for high voltage-activated ca(2+) influx in anterior pituitary lactotrophs and somatotrophs.

Journal of neuroendocrinology·2012
Same author

The function of the adrenocortical axis in permanent middle cerebral artery occlusion: effect of glucocorticoids on the neurological outcome.

Brain research·2011
Same author

Cellular prion protein co-localizes with nAChR beta4 subunit in brain and gastrointestinal tract.

The European journal of neuroscience·2008
Same author

Rasmussen encephalitis with active inflammation and delayed seizures onset.

Neurology·2004

Copaxone prolonged prion disease incubation in hamsters by affecting the initial infection process. This immunomodulatory drug reduced prion (PrPSc) binding and accumulation in vitro, suggesting a novel therapeutic mechanism.

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Prion diseases are characterized by the accumulation of misfolded prion protein (PrPSc).
  • The immune system and inflammation play a role in prion disease pathogenesis.
  • Copaxone is an immunomodulatory drug used to treat multiple sclerosis.

Purpose of the Study:

  • To investigate the effect of Copaxone on prion disease manifestation in scrapie-infected hamsters.
  • To explore the mechanism by which Copaxone might influence prion infection.

Main Methods:

  • Copaxone administration to hamsters at different time points relative to prion infection.
  • In vitro experiments assessing PrPSc binding to cells and heparin beads.
  • Evaluation of PrPSc accumulation in scrapie-infected cells treated with Copaxone.

Related Experiment Videos

Main Results:

  • Copaxone prolonged prion disease incubation by approximately 30 days when administered at the time of infection or mixed with the inoculum.
  • Copaxone demonstrated no effect when treatment began 2 weeks post-infection.
  • In vitro, Copaxone reduced PrPSc binding to cells and heparin beads, and inhibited PrPSc accumulation in infected cells.

Conclusions:

  • Copaxone may delay prion infection by interfering with the interaction between PrPSc and glycosaminoglycans.
  • The findings suggest a potential therapeutic role for Copaxone in early-stage prion infections.
  • Further research is needed to determine if Copaxone's immunomodulatory activity is linked to its anti-prion effects.